PATENT CLAIM ANALYSIS

Application Number: 16030541
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-06
Patent Classification: ["514", "018300"]

Abstract:
In some aspects, the present invention provides methods of treating a subject in need of treatment for neuropathic pain, the method comprising administering a compstatin analog to the subject. In some embodiments, the compstatin analog is administered parenterally, e.g., intravenously.

Claim (Index 23):
The composition of  claim 22 , wherein the compstatin analog is a compound that comprises a cyclic peptide having a core sequence of X\u2032aa-Gln-Asp-Xaa-Gly (SEQ ID NO: 3), where X\u2032aa and Xaa are selected from Trp and analogs of Trp.

Metadata:
- Claim Count in Document: 28.0
- Percentile: 95.0
- Lexical Diversity: 1.46875
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13805538', '11544389', '13409941', '12525799', '14775663']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7481119715350012
- 35 USC 102 Novelty (BERT): 0.5562558159383569
- Combined Prediction Score: 0.7289263559753367
- Mean Citation Score: 305.559412
- Max Citation Score: 401.38126
- Similarity Product: 368.3345885207701

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test